← Back

Wire · operational-macro

FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection

Published

10 November 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at urologytimes.com →

◆ Verified

Fusion42 · 11 November 2026 · Fusion42 review

The FDA has granted De Novo authorization to the Virtuoso Endoscopy System, a robotic platform enabling en bloc resection of bladder tumors with better specimen quality and surgeon precision. Virtuoso Surgical plans to launch the system in US urology centers in 2027, backed by positive clinical trial results showing safety and effectiveness.

This Wire brief sits within Fusion42's coverage of Medtech, and 5 sources have reported it between 10 Nov 2026 and 16 Nov 2026.

◆ ◆ The Wire takeaway

You can now build solutions around the FDA-cleared Virtuoso robotic system that improves bladder tumor removal quality. Surgical founders in medtech can expect a new market opening as adoption grows in US urology centres.

◆ Coverage

5 sources · first reported 10 Nov 2026 · latest 16 Nov 2026

◆ Related on Wire

◆ Topics

MedtechFDA-approvalrobotic-surgerybladder-cancermedtechclinical-trials